Market Overview - A-shares showed mixed performance with the Shanghai Composite Index down 0.01%, Shenzhen Component Index up 0.19%, and ChiNext Index down 0.29% as of market close [1] - Total trading volume in Shanghai, Shenzhen, and Beijing reached 25,568 billion, an increase of 756 billion from the previous day [1] ETF Performance - The China-Korea Semiconductor ETF surged by 9.64%, leading the market, driven by the recovery in the semiconductor supply chain [2] - The National 2000 ETF rose by 5.04%, indicating a rebound in small-cap growth stocks [2] - The Electric Grid sector performed well, with the Electric Grid ETF up 3.23% and the Electric Grid Equipment ETFs rising by 3.22% and 2.91% respectively [2] Communication Sector - The communication sector also saw gains, with ETFs in this category rising between 2.73% and 2.78% [3] Declining Sectors - The pharmaceutical sector faced a broad retreat, with the Hang Seng Biotechnology ETF showing the largest decline at -3.89% [4] - Other related ETFs in the healthcare and biotechnology sectors also experienced significant drops, indicating a market shift from defensive sectors to technology growth [4] Trading Activity - The Short-term Bond ETF had a trading volume exceeding 66 billion, leading in activity among ETFs [5] - The top traded ETFs included the Short-term Bond ETF at 661.12 billion and the Silver Day Benefit ETF at 167.16 billion [5] Turnover Rates - Cross-border products showed high trading activity, with the Brazil ETF and China-Korea Semiconductor ETF having turnover rates of 171.99% and 125.76% respectively [6][7] - The National Debt ETF also maintained a strong turnover rate of 88.09%, indicating active trading in interest rate bonds and cross-border assets [7] New ETF Launch - A new Technology Growth ETF by Industrial Bank is set to launch on February 27, with a focus on hard technology and a multi-factor strategy targeting the top 50 securities in various tech sectors [8]

Core Insights - The capital market has entered a recovery phase since September 24, 2024, with the Hang Seng Biotechnology Index showing a cumulative increase of 78.6%, outperforming the Hong Kong Stock Connect Innovative Drug Index, indicating high elasticity and a strong Sharpe ratio [1][4]. Performance Metrics - Annualized Return: Hang Seng Biotechnology Index at 59.42%, compared to 57.50% for Hong Kong Stock Connect Innovative Drug Index [3]. - Annualized Volatility: Hang Seng Biotechnology Index at 41.03%, slightly lower than the Hong Kong Stock Connect Innovative Drug Index at 42.66% [3]. - Maximum Drawdown: Hang Seng Biotechnology Index at -27.55%, which is comparable to other indices [3]. - Sharpe Ratio: Hang Seng Biotechnology Index leads with a ratio of 1.45, outperforming other related indices [3][4]. - Cumulative Return since 2025: Hang Seng Biotechnology Index at 67.50%, again showing superiority over similar indices [4]. Index Characteristics - The Hang Seng Biotechnology Index is the only Hong Kong medical theme index with index futures, enhancing investment strategies and liquidity [6][7]. - The introduction of index futures in November 2025 is expected to improve liquidity and attract more investment [6][7]. - The index has shown strong trading activity, with an average daily turnover of approximately 16 billion yuan in 2015 [6]. Regulatory Framework - The 18A system in Hong Kong provides a unique listing channel for unprofitable biotech companies, enhancing the attractiveness of the Hong Kong market for international capital [9][11]. - Over 70 biotech companies have listed under the 18A system, which is more flexible compared to similar regulations in other markets [11]. Investment Opportunities - The Hang Seng Biotechnology ETF (Code: 520933) is positioned as an optimal choice for investors looking to participate in the biotech sector with lower entry barriers [12].

Group 1 - The core viewpoint of the article highlights that AI technology is driving innovation in the pharmaceutical sector, with Nvidia and Eli Lilly collaborating to establish an AI+Pharmaceutical Innovation Lab, planning to invest up to $1 billion over the next five years to enhance drug development productivity [1] - TempusAI's performance indicates that AI has a high replicability in clinical testing and the commercialization of medical data, showcasing the potential of AI in transforming the pharmaceutical industry [1] - The current phase in the pharmaceutical industry is characterized by a resonance of technological breakthroughs, active funding, and accelerated application of AI technology, pushing the industry towards a data and algorithm-driven transformation [1] Group 2 - The Hang Seng Biotechnology Index focuses on innovative drugs, highlighting three key advantages: leading companies, scarce futures, and high elasticity & high Sharpe ratio [1] - Investors looking to conveniently participate in core leading innovative drugs can consider the Hang Seng Biotechnology ETF from Guotai (520933) for a streamlined investment approach [1]